Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
Status:
Withdrawn
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and
children with relapsed NBL have an overall 3 year survival rate of < 10%. Hematopoietic Stem
Cell Transplant from a different donor (allogeneic), is a form of adoptive cellular therapy ,
such that infused donor cells find host tumors as foreign and fight them. After transplant,
the donor immune cells (i.e. T cells, NK cells) mediate Graft versus Tumor (GVT) effect and
may stop tumor from recurring. Also,reduced intensity transplants lead to minimal toxicity
and less risk of mortality in heavily pre-treated NBL patients.
PURPOSE: This phase II trial is studying how well giving a reduced intensity(using
Fludarabine, Busulfan and antithymocyte globulin)preparative regimen followed by donor stem
cell transplant works in treating young patients with high-risk neuroblastoma that has
relapsed or not responded to treatment.